APLSApellis Pharmaceuticals, Inc.

Nasdaq apellis.com


$ 41.03 $ 1.76 (4.48 %)    

Friday, 06-Sep-2024 15:59:48 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 41.05
$ 28.42 x 1,800
$ 41.04 x 100
-- - --
$ 33.49 - $ 73.80
1,852,052
na
5B
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-01-2023 09-30-2023 10-Q
5 07-31-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-21-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 04-28-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-02-2020 09-30-2020 10-Q
17 07-30-2020 06-30-2020 10-Q
18 04-29-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 07-31-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 07-31-2018 06-30-2018 10-Q
26 04-30-2018 03-31-2018 10-Q
27 03-19-2018 12-31-2017 10-K
28 12-20-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-apellis-pharmaceuticals-lowers-price-target-to-64

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...

 ubs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-83

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $85 to ...

 wedbush-maintains-neutral-on-apellis-pharmaceuticals-raises-price-target-to-41

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from ...

 goldman-sachs-maintains-buy-on-apellis-pharmaceuticals-raises-price-target-to-74

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target...

 baird-maintains-outperform-on-apellis-pharmaceuticals-raises-price-target-to-96

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...

 needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

 apellis-pharmaceuticals-pegcetacoplan-meets-primary-goal-in-late-stage-study-in-patients-with-rare-kidney-diseases

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan f...

 apellis-and-sobi-announce-phase-3-valiant-study-results-for-pegcetacoplan-in-rare-kidney-diseases-achieves-68-reduction-in-proteinuria-consistent-across-all-subgroups-data-submission-planned-for-us-and-eu

Apellis To Host Conference Call At 8:00 AM ET

 hc-wainwright--co-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-83

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...

 goldman-sachs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-66

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target...

 needham-reiterates-buy-on-apellis-pharmaceuticals-maintains-85-price-target

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.

 jefferies-maintains-buy-on-apellis-pharmaceuticals-maintains-80-price-target

Jefferies analyst Akash Tewari maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

 watching-apellis-pharmaceuticals-traders-circulate-comments-from-jefferies-suggesting-the-fda-has-put-out-a-faers-update-which-included-a-new-additional-death-on-syfovre-says-does-not-change-our-view-on-syfovres-safety

https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

 baird-maintains-outperform-on-apellis-pharmaceuticals-lowers-price-target-to-86

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target fro...

 baird-maintains-outperform-on-apellis-pharmaceuticals-maintains-100-price-target

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION